Increasing prevalence of growth hormone deficiency is driving
demand for innovative therapies and personalized treatment
approaches in the market.
WILMINGTON, Del., July 18, 2024 /PRNewswire/ -- The global growth
hormone deficiency market is estimated to ascend at a CAGR
of 4.4% from 2024 to 2034. Transparency Market Research
projects that the overall sales revenue for growth hormone
deficiency is estimated to reach US$
7 billion by the end of 2034.
A notable trend is the increasing focus on digital health
solutions. Telemedicine and digital platforms are facilitating
remote patient monitoring, enhancing treatment adherence, and
improving overall patient outcomes. These technologies are
particularly beneficial in regions with limited healthcare access,
thereby expanding the reach of growth hormone deficiency
therapies.
Personalized medicine is gaining traction within the growth
hormone deficiency market. Advancements in genetic testing and
biomarker identification allow for more precise diagnosis and
tailored treatment plans. This approach not only improves treatment
efficacy but also minimizes adverse effects, optimizing patient
care.
Download Sample of the Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86221
There is a growing interest in combination therapies and novel
drug delivery systems. Companies are exploring synergistic effects
of multiple therapies and developing innovative delivery methods to
enhance therapeutic outcomes and patient convenience. These trends
underscore the dynamic evolution of the growth hormone deficiency
market, driven by technological innovation, sustainability goals,
and personalized healthcare approaches.
Key Findings of the Market Report
- Recombinant human growth hormone is the dominant treatment type
segment in the growth hormone deficiency market, leading with
innovative therapies and widespread adoption.
- The dominant disease indication segment in the growth hormone
deficiency market is pediatric growth hormone deficiency, driven by
high diagnosis and treatment rates.
- Subcutaneous administration dominates the growth hormone
deficiency market due to ease, patient preference, and advancements
in delivery technology.
Growth Hormone Deficiency Market Growth Drivers &
Trends
- Significant investments in biotechnology and personalized
medicine are driving market growth.
- Increasing awareness and improving healthcare access drive
rapid market growth.
- Innovations in gene therapy and drug delivery systems intensify
competition.
- New product approvals and regulatory support are crucial for
market entry and growth.
- Variations in healthcare infrastructure influence regional
market dynamics.
Growth Hormone Deficiency Market Report Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 4.3 Bn
|
Forecast (Value) in
2034
|
US$ 7.0 Bn
|
Growth Rate
(CAGR)
|
4.4 %
|
No. of
Pages
|
145
Pages
|
Segments
covered
|
By Treatment Type, By
Disease Indication, By Route of Administration, By Distribution
Channel, By Region
|
Growth Hormone Deficiency Market: Competitive
Landscape
The growth hormone deficiency market is highly competitive,
driven by the increasing prevalence of growth hormone deficiency
and advancements in biotechnology. Key players such as Pfizer, Novo
Nordisk, Eli Lilly, and Merck KGaA dominate the landscape with
established recombinant human growth hormone (rhGH) therapies.
Emerging biopharmaceutical companies like Ascendis Pharma and OPKO
Health are disrupting the market with innovative long-acting
formulations and novel delivery systems.
Ongoing research into gene therapy and personalized medicine is
intensifying competition. Strategic collaborations, robust research
and development pipelines, and regulatory approvals are critical
factors influencing market share and driving the dynamic and
competitive nature of the growth hormone deficiency market. Some
prominent players are as follows:
- Novo Nordisk A/S
- Pfizer Inc.
- Merck KGaA
- Eli Lilly and Company
- Novartis AG
- Hoffmann-La Roche AG
- Ipsen Pharma
- Ferring Pharmaceuticals
- Anhui Anke Biotechnology (Group) Co. Ltd.
- Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.
Product Portfolio
- Ipsen Pharma is a global biopharmaceutical group dedicated
to improving patients' lives through innovative medicines in
oncology, neuroscience, and rare diseases. By combining
advanced research with a patient-centric approach, Ipsen delivers
targeted therapies that address unmet medical needs and enhance
quality of life.
- Ferring Pharmaceuticals specializes in the development and
delivery of groundbreaking therapies in reproductive medicine,
maternal health, gastroenterology, and urology. Committed to
patient care and scientific advancement, Ferring's innovative
solutions support people throughout key stages of their lives,
enhancing health and well-being globally.
Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86221
Global Growth Hormone Deficiency Market: Regional
Profile
- North America dominates the
market, driven by high healthcare spending, sophisticated
biotechnology, and the presence of significant firms like as
Pfizer and Eli Lilly. The United
States leads, with high diagnostic rates and extensive use
of recombinant human growth hormone therapy.
- In Europe, the market is
driven by considerable research and development activity and
advantageous reimbursement policies, with Germany, France, and the United Kingdom leading the way. The
Asia-Pacific area is expanding
rapidly, thanks to more knowledge, better healthcare access, and
rising disposable incomes. Countries such as China and Japan are important markets, with government
programs promoting market growth.
- Latin America, the
Middle East, and Africa see slow development, hampered by poor
healthcare infrastructure and economic constraints. Improved
healthcare facilities and increased investment in biotechnology
offer prospective chances for market penetration in these
countries.
Growth Hormone Deficiency Market: Key Segments
By Treatment Type
- Therapeutic Treatment
- Norditropin
- Genotropin
- Humatrope
- Saizen
- Others (Omnitrope, etc.)
- Recombinant Human Growth Hormone
- Human Pituitary Gland Extracts
- Surgery
By Disease Indication
- Pediatric Growth Hormone Deficiency
- Idiopathic Short Stature
- Small for Gestational Age
- Turner Syndrome
- Adult Growth Hormone Deficiency
- Others (Prader-Willi Syndrome, etc.)
By Route of Administration
- Subcutaneous
- Intramuscular
- Intravenous
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research
Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=86221<ype=S
More Trending Report by Transparency Market Research:
- Global Biosensors Market to Reach US$ 48.49 Billion by 2031, Expanding at a CAGR
of 7.2%
- IV Bags Market Predicted to Reach USD 1.5 billion by 2032, Expanding at a CAGR
of 5.8%: TMR Report
- Epidermal Growth Factors (EGFs) Market is expected to
grow at a CAGR of 11.3% from 2024 to 2034 and reach US$ 3.7 Bn by the end of 2034
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE
HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow
Us: LinkedIn| Twitter| Blog | YouTube
Logo
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/growth-hormone-deficiency-market-poised-to-reach-us-7-billion-by-2034-driven-by-advances-in-combination-therapies-and-innovative-drug-delivery-systems-tmr-302200610.html